FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1868607547> ?p ?o ?g. }

• W1868607547 endingPage "205" @default.
• W1868607547 startingPage "203" @default.
• W1868607547 abstract "The 15th anniversary of the registration of mifepristone in the United States (US) provides an opportunity to reflect on its history, its contribution to women's reproductive health and to consider its promising future as a therapeutic agent. Mifepristone was first approved by the Food and Drug Administration (FDA) as part of a medical regimen to induce abortion in the early first trimester, and most recently in 2012, it was registered in a different formulation as an antiglucocorticoid for the treatment of Cushing's syndrome [[1]United States Food and Drug Administration FDA approves Korlym for patients with endogenous Cushing’s syndrome: FDA news release.http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm292462.htmDate: 2012Google Scholar]. Furthermore, years of scientific research have demonstrated the utility of mifepristone for a variety of off-label obstetric and gynecologic indications. Evidence-based alternative use of registered drugs for indications other than those on their approved labels is commonplace in the US and allowable under FDA policy [2Use of approved drugs for unlabeled indications.FDA Drug Bull. 1982; 12: 4-5Google Scholar, 3Nightingale S.L. Off-label use of prescription drugs.Am Fam Physician. 2003; 68: 425-427PubMed Google Scholar]. There are numerous examples of registered drugs that are widely used off-label safely and effectively for obstetric and gynecologic conditions, such as misoprostol to induce cervical ripening and uterine contractions, methotrexate to treat ectopic pregnancy, and magnesium sulfate as a treatment for preeclampsia. Mifepristone is now used in the management of second-trimester pregnancy terminations, both as part of nonsurgical uterine evacuation regimens, as well as for cervical preparation prior to surgical dilation and extraction (D&E) procedures. Second-trimester medical abortion is increasingly utilized around the world, replacing surgical methods that are predominantly offered in higher-level secondary or tertiary level facilities and require providers with specialized training. Now that instillation methods are considered obsolete due to high rates of serious adverse events, the World Health Organization recommends second-trimester medical induction with either mifepristone–misoprostol regimens or misoprostol alone (when mifepristone is not available), as do other global health authorities, such as The International Federation of Gynecology and Obstetrics, Royal College of Obstetrics and Gynaecologists (RCOG) and American College of Obstetricians and Gynecologists [4World Health Organization Safe abortion: technical and policy guidance for health systems.2nd ed. World Health Organization, Geneva2012Google Scholar, 5Royal College of Obstetricians and Gynaecologists The care of women requesting induced abortion: evidence-based clinical guideline number 7.https://www.rcog.org.uk/globalassets/documents/guidelines/abortion-guideline_web_1.pdfDate: 2011Google Scholar, 6International Federation of Gynecology and Obstetrics (FIGO) Misoprostol recommended dosages 2012.http://www.figo.org/sites/default/files/uploads/project-publications/Miso/Misoprostol_Recommended%20Dosages%202012.pdfGoogle Scholar, 7American College of Obstetricians and Gynecologists Second-trimester abortion. Practice bulletin no. 135.Obstet Gynecol. 2013; 121: 1394-1406Crossref PubMed Google Scholar]. Pretreatment with mifepristone increases the complete expulsion rate of misoprostol alone from approximately 70% to more than 90% and decreases time to expulsion by up to 50% in second-trimester inductions. Furthermore, adding mifepristone to the prostaglandin-only regimen requires fewer repeated misoprostol doses, thereby reducing side effects [8Dabash R. Chelli H. Hajri S. Shochet T. Raghavan S. Winikoff B. A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14-21 weeks of pregnancy.Int J Gynaecol Obstet. 2015; 11: 40-44Abstract Full Text Full Text PDF Scopus (30) Google Scholar, 9Ngoc N.T. Shochet T. Raghavan S. Blum J. Nga N.T. Minh N.T. et al.Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial.Obstet Gynecol. 2011; 118: 601-608Crossref PubMed Scopus (63) Google Scholar, 10Kapp N. Borgatta L. Stubblefield P. Vragovic O. Moreno N. Mifepristone in second-trimester medical abortion: a randomized controlled trial.Obstet Gynecol. 2007; 110: 1304-1310Crossref PubMed Scopus (64) Google Scholar] and improving the patient experience overall. Similar to medical induction with a live fetus, the combined regimen of mifepristone and misoprostol is also proving highly effective for labor induction after intrauterine fetal demise in the second and third trimesters [[11]Wagaarachchi P.T. Ashok P.W. Narvekar N.N. Smith N.C. Templeton A. Medical management of late intrauterine death using a combination of mifepristone and misoprostol.BJOG. 2002; 109: 443-447Crossref PubMed Scopus (60) Google Scholar] and can reduce expulsion time by nearly four hours (from 16 to 10 hours) in comparison to misoprostol alone [12Sharma D. Singhal S.R. Poonam Paul A. Kunika Comparison of mifepristone combination with misoprostol and misoprostol alone in the management of intrauterine death: condensation - misoprostol and mifepristone combination is more effective than misoprostol alone in the management of intrauterine death.Taiwan J Obstet Gynecol. 2011; 50: 322-325Abstract Full Text Full Text PDF PubMed Scopus (16) Google Scholar, 13Stibbe K.J. de Weerd S. Induction of delivery by mifepristone and misoprostol in termination of pregnancy and intrauterine fetal death: 2nd and 3rd trimester induction of labour.Arch Gynecol Obstet. 2012; 286: 795-796Crossref PubMed Scopus (8) Google Scholar]. Timely evacuation can alleviate emotional distress and reduce the possibility of developing rare complications due to delayed care, such as infection, hemorrhage and disseminated intravascular coagulopathy [14Shulman L.P. Lipscomb G.H. Ling F.W. Management of abnormal pregnancies.in: Paul M. Lichtenberg E.S. Borgatta L. Grimes D.A. Stubblefield P.G. A Clinician’s Guide to Medical and Surgical Abortion. W.B. Saunders Company, Castro Valley, CA1999Google Scholar, 15Romero R. Copel J.A. Hobbins J.C. Intrauterine fetal demise and hemostatic failure: the fetal death syndrome.Clin Obstet Gynecol. 1985; 28: 24-31Crossref PubMed Scopus (20) Google Scholar]. Despite the absence of large prospective randomized controlled trials, the combined mifepristone–prostaglandin regimen is currently recommended as first-line treatment for late intrauterine death and stillbirth by RCOG [[16]Royal College of Obstetricians and Gynaecologists (RCOG) Late intrauterine fetal death and stillbirth. Royal College of Obstetricians and Gynaecologists (RCOG), London (UK)2010Google Scholar]. Mifepristone has been tested as an adjunct to osmotic dilators for cervical preparation prior to D&E to maximize safety and decrease the patient burden associated with multiday procedures [17Edelman A.B. Buckmaster J.G. Goetsch M.F. Nichols M.D. Jensen J.T. Cervical preparation using laminaria with adjunctive buccal misoprostol before second-trimester dilation and evacuation procedures: a randomized clinical trial.Am J Obstet Gynecol. 2006; 194: 425-430Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, 18Fox M.K.C. Cervical preparation for second-trimester surgical abortion prior to 20 weeks' gestation: SFP guideline #2013-4.Contraception. 2014; 89: 75-84Abstract Full Text Full Text PDF PubMed Scopus (51) Google Scholar]. Recent data show modest, yet promising, results that the addition of mifepristone to osmotic dilators alone may shorten the total procedure time and improve cervical dilation, thereby facilitating the procedure and enhancing provider satisfaction with the preparation [[19]Goldberg A. Fitzmaurice G. Fortin J. McKetta S. Dean G. Drey E. et al.Cervical preparation before second-trimester dilation and evacuation: a multicenter randomized trial comparing osmotic dilators alone to dilators plus adjunctive misoprostol or mifepristone. Oral abstract presentation O1.Contraception. 2014; 90: 292Abstract Full Text Full Text PDF Google Scholar]. Cervical preparation with a combination of mifepristone, osmotic dilators and misoprostol may reduce the number of osmotic dilators needed and shorten the number of pretreatment visits required when compared to osmotic dilators and misoprostol only [[20]Shaw K.A. Shaw J.G. Hugin M. Velasquez G. Hopkins F.W. Blumenthal P.D. Adjunct mifepristone for cervical preparation prior to dilation and evacuation: a randomized trial.Contraception. 2015; 91: 313-319Abstract Full Text Full Text PDF PubMed Scopus (18) Google Scholar]. While this area of investigation is relatively new, it is possible that mifepristone will have an adjunctive role in combination with osmotic dilators in the provision of D&Es performed later in gestation. The evidence base for mifepristone in obstetrics and gynecology includes its use as a cervical priming agent and for induction of labor at term [21Stenlund P.M. Ekman G. Aedo A.R. Bygdeman M. Induction of labor with mifepristone—a randomized, double-blind study versus placebo.Acta Obstet Gynecol Scand. 1999; 78: 793-798Crossref PubMed Scopus (63) Google Scholar, 22McGill J. Shetty A. Mifepristone and misoprostol in the induction of labor at term.Int J Gynaecol Obstet. 2007; 96: 80-84Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar, 23Tenore J.L. Methods for cervical ripening and induction of labor.Am Fam Physician. 2003; 67: 2123-2128PubMed Google Scholar]. One randomized controlled trial demonstrated that women who received mifepristone were twice as likely to present a ripe cervix and/or go into labor within 48 hours when compared to placebo. The infants born to women exposed to mifepristone had slightly lower Apgar scores at 1 min, but that difference was mitigated at 5 and 10 min [[21]Stenlund P.M. Ekman G. Aedo A.R. Bygdeman M. Induction of labor with mifepristone—a randomized, double-blind study versus placebo.Acta Obstet Gynecol Scand. 1999; 78: 793-798Crossref PubMed Scopus (63) Google Scholar]. Even though these research findings are encouraging, pharmaceutical companies remain reluctant to register mifepristone for this indication due to liability concerns around its use with a live fetus and wanted baby. Early pregnancy loss (EPL), specifically anembryonic gestation and embryonic/fetal demise, is another potential off-label therapeutic application of mifepristone. Misoprostol alone is recommended as an alternative to suction curettage for active management of first-trimester EPL in the US [[24]Practice bulletin no. 150: early pregnancy loss.Obstet Gynecol. 2015; 125: 1258-1267Crossref PubMed Scopus (111) Google Scholar]; many European countries use mifepristone and misoprostol to induce tissue expulsion for early pregnancy demise [[25]Colleselli V. Schreiber C.A. D'Costa E. Mangesius S. Wildt L. Seeber B.E. Medical management of early pregnancy failure (EPF): a retrospective analysis of a combined protocol of mifepristone and misoprostol used in clinical practice.Arch Gynecol Obstet. 2014; 289: 1341-1345Crossref PubMed Scopus (7) Google Scholar]. To date, the published literature shows much variation in efficacy of mifepristone–misoprostol regimens, which ranges from 65 to 95% [26Stockheim D. Machtinger R. Wiser A. Dulitzky M. Soriano D. Goldenberg M. et al.A randomized prospective study of misoprostol or mifepristone followed by misoprostol when needed for the treatment of women with early pregnancy failure.Fertil Steril. 2006; 86: 956-960Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar, 27Grønlund A. Grønlund L. Clevin L. Andersen B. Palmgren N. Lidegaard Ø. Management of missed abortion: comparison of medical treatment with either mifepristone+misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen County, Denmark.Acta Obstet Gynecol Scand. 2002; 81: 1060-1065Crossref PubMed Google Scholar, 28Wagaarachchi P.T. Ashok P.W. Narvaekar N. Smith N.C. Templeton A. Medical management of early fetal demise using a combination of mifepristone and misoprostol.Hum Reprod. 2001; 16: 1849-1853Crossref PubMed Scopus (45) Google Scholar, 29el-Refaey H. Hinshaw K. Henshaw R. Smith N. Templeton A. Medical management of missed abortion and anembryonic pregnancy.BMJ. 1992; 305: 1399Crossref PubMed Scopus (91) Google Scholar, 30Kushwah B. Singh A. Sublingual versus oral misoprostol for uterine evacuation following early pregnancy failure.Int J Gynaecol Obstet. 2009; 106: 43-45Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar, 31Schreiber C.A. Creinin M.D. Reeves M.F. Harwood B.J. Mifepristone and misoprostol for the treatment of early pregnancy failure: a pilot clinical trial.Contraception. 2006; 74: 458-462Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar]. It is likely that the discrepancies are attributable to small sample sizes, the type of pregnancy failure (anembryonic gestation vs. embryonic fetal death), women presenting with or without bleeding, misoprostol dose, the timing of the follow-up visit and criteria used to define success. Research is ongoing to determine the clinical advantage of using mifepristone and misoprostol together for treatment of missed abortion. Clinicians around the world, and especially in the US, may be largely unaware of the advantage conferred by using mifepristone for indications other than early first-trimester abortion. As we see with numerous other drugs, off-label use for new indications is often incorporated into clinical practice in advance of, or without, a label change. For example, antidepressants are not approved by the FDA as a treatment for neuropathic pain; nevertheless they are now considered a first-line treatment option [[32]Dworkin R.H. O'Connor A.B. Audette J. Baron R. Gourlay G.K. Haanpää M.L. et al.Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.Mayo Clin Proc. 2010; 85: S3-S14Abstract Full Text Full Text PDF PubMed Scopus (1055) Google Scholar]. The benefits to a drug manufacturer of updating the label in accordance with the current evidence may be outweighed by the very costly and laborious process required, particularly when off-label use is legal and there is no competing product on the market. But American women's access to mifepristone has become restricted. Several US states have passed laws requiring mifepristone to be used strictly in accordance with the label, despite the fact that off-label regimens for first-trimester medical abortion are more effective and less expensive and result in fewer side effects. In those states, off-label use for second-trimester medical abortion, labor induction and cervical preparation as described above are also prohibited. How can we ensure continued access to the benefits of mifepristone for the women who reside in those states and in other states that may follow suit? A label change would improve access for women, and facilitate use commensurate with the current evidence. Alternatively, the registration of additional mifepristone products, possibly for other indications, could broaden mifepristone use in the US. Mifepristone facilitates uterine evacuation in a variety of clinical conditions and is therefore important for women's health. As the barriers to access and evidence-based use multiply, it may be time, 15 years later, to address unnecessary restrictions on use by expanding indications formally through a label change." @default.
• W1868607547 created "2016-06-24" @default.
• W1868607547 creator A5004241923 @default.
• W1868607547 creator A5005089052 @default.
• W1868607547 creator A5018285680 @default.
• W1868607547 date "2015-09-01" @default.
• W1868607547 modified "2023-09-28" @default.
• W1868607547 title "Off-label indications for mifepristone in gynecology and obstetrics" @default.
• W1868607547 cites W1969733684 @default.
• W1868607547 cites W1969968596 @default.
• W1868607547 cites W1974377866 @default.
• W1868607547 cites W1978158379 @default.
• W1868607547 cites W1995752448 @default.
• W1868607547 cites W1996596390 @default.
• W1868607547 cites W1997994409 @default.
• W1868607547 cites W2006801744 @default.
• W1868607547 cites W2011282429 @default.
• W1868607547 cites W2022986456 @default.
• W1868607547 cites W2035362535 @default.
• W1868607547 cites W2038318392 @default.
• W1868607547 cites W2041120294 @default.
• W1868607547 cites W2044036242 @default.
• W1868607547 cites W2053822073 @default.
• W1868607547 cites W2059107250 @default.
• W1868607547 cites W2084567915 @default.
• W1868607547 cites W2131330022 @default.
• W1868607547 cites W2142662718 @default.
• W1868607547 cites W2156038813 @default.
• W1868607547 cites W4238276918 @default.
• W1868607547 cites W4239080680 @default.
• W1868607547 cites W4243853565 @default.
• W1868607547 doi "https://doi.org/10.1016/j.contraception.2015.06.021" @default.
• W1868607547 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26141817" @default.
• W1868607547 hasPublicationYear "2015" @default.
• W1868607547 type Work @default.
• W1868607547 sameAs 1868607547 @default.
• W1868607547 citedByCount "0" @default.
• W1868607547 crossrefType "journal-article" @default.
• W1868607547 hasAuthorship W1868607547A5004241923 @default.
• W1868607547 hasAuthorship W1868607547A5005089052 @default.
• W1868607547 hasAuthorship W1868607547A5018285680 @default.
• W1868607547 hasBestOaLocation W18686075471 @default.
• W1868607547 hasConcept C10885799 @default.
• W1868607547 hasConcept C131872663 @default.
• W1868607547 hasConcept C2778826759 @default.
• W1868607547 hasConcept C2779234561 @default.
• W1868607547 hasConcept C29456083 @default.
• W1868607547 hasConcept C54355233 @default.
• W1868607547 hasConcept C71924100 @default.
• W1868607547 hasConcept C86803240 @default.
• W1868607547 hasConceptScore W1868607547C10885799 @default.
• W1868607547 hasConceptScore W1868607547C131872663 @default.
• W1868607547 hasConceptScore W1868607547C2778826759 @default.
• W1868607547 hasConceptScore W1868607547C2779234561 @default.
• W1868607547 hasConceptScore W1868607547C29456083 @default.
• W1868607547 hasConceptScore W1868607547C54355233 @default.
• W1868607547 hasConceptScore W1868607547C71924100 @default.
• W1868607547 hasConceptScore W1868607547C86803240 @default.
• W1868607547 hasIssue "3" @default.
• W1868607547 hasLocation W18686075471 @default.
• W1868607547 hasLocation W18686075472 @default.
• W1868607547 hasOpenAccess W1868607547 @default.
• W1868607547 hasPrimaryLocation W18686075471 @default.
• W1868607547 hasRelatedWork W2005899497 @default.
• W1868607547 hasRelatedWork W2334852907 @default.
• W1868607547 hasRelatedWork W2350922817 @default.
• W1868607547 hasRelatedWork W2354522140 @default.
• W1868607547 hasRelatedWork W2359673640 @default.
• W1868607547 hasRelatedWork W2372293303 @default.
• W1868607547 hasRelatedWork W2372512466 @default.
• W1868607547 hasRelatedWork W2376383948 @default.
• W1868607547 hasRelatedWork W2387319213 @default.
• W1868607547 hasRelatedWork W3193409905 @default.
• W1868607547 hasVolume "92" @default.
• W1868607547 isParatext "false" @default.
• W1868607547 isRetracted "false" @default.
• W1868607547 magId "1868607547" @default.
• W1868607547 workType "article" @default.